However, when blood samples from metastatic CRC patients were examined, CD16−/CD11b− EMCs (3.8 ± 1.24, P < 0.05), CD16−/CD11b+ EMCs (2.2 ± 0.86, P < 0.05), and CD16+/CD11b+ EMCs (7.6 ± 3.1, P < 0.05) were significantly increased compared to both LARC patients and HD. This evidence concerns the gene ITGAM and colorectal carcinoma.